Bone MicroArchitecture in Acromegaly
Completed
Conditions studied: Acromegaly, Osteoporosis Risk
In brief
The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least 1 year and with normal insulin-like growth factor-1 (IGF-1) levels. This study aims to describe the bone architecture and associated biochemical indices of bone turnover and metabolism in patients with active acromegaly and how these are altered with treatment of the disease.
Key facts
- Study ID
- NCT03225040
- Run by
- Columbia University
- People needed
- 77
- Starts
- 2016-08-03
- Expected to finish
- 2019-12-21
- Last updated by the study team
- 2021-07-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Individuals with acromegaly
- On pegvisomant therapy with a normal IGF-1 level for at least 1 year
You may not qualify if…
- Malignancy (except cured basal, squamous cell skin carcinoma or other cured cancers free from recurrence > 3 years)
- Pregnancy or lactation within last 12 months
- Untreated primary hyperparathyroidism, hyper- or hypothyroidism
- Cushing's syndrome
- Prolactin-secreting pituitary adenoma
- GH deficiency
- On current drug therapy for osteoporosis
- Diabetes mellitus
- Renal insufficiency
- Liver disease
- Current or past use of glucocorticoids (more than physiologic dose), anticonvulsants, anticoagulants, methotrexate, aromatase inhibitors
Where it is running
- Neuroendocrine Unit and Pituitary Center, Columbia University — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.